hVIVO CEO on growth plans and human challenge trials

hVIVO PLC reported H1 2025 revenue exceeding £24 million and EBITDA of approximately £3 million, supported by cancellation fees and operational efficiencies, with cash reserves over £23 million and a weighted order book of £40 million. Despite broader CRO industry headwinds leading to trial postponements, CEO Yamin Khan emphasized the continued relevance of human challenge trials for accelerated, cost-effective drug development, alongside successful integration of CRS and Cryo Store, which has generated £1 million in annualised savings and £3 million in cross-selling. The company projects FY 2025 revenue of £47 million with a small single-digit EBITDA loss, anticipating a return to growth in 2026.

Analysis

hVIVO PLC reported a mixed performance for H1 2025, with revenue of just over £24 million and a seemingly robust EBITDA of approximately £3 million. However, this profitability was materially supported by the recognition of one-off postponement and cancellation fees, alongside operational efficiencies, rather than purely from core business growth. Management acknowledges significant industry-wide headwinds, particularly in the vaccine sector, which have resulted in longer sales cycles and trial delays. The full-year 2025 forecast underscores this pressure, guiding for approximately £47 million in revenue and a small single-digit EBITDA loss. This implies a notable negative EBITDA swing in the second half of the year, reversing H1's fee-driven profit. Despite the near-term challenges, strategic progress is evident. The company maintains a solid balance sheet with over £23 million in cash and a weighted contracted order book of £40 million, providing some revenue visibility. Furthermore, the integration of the CRS and Cryo Store acquisitions is yielding tangible results, with £1 million in annualised savings and £3 million in cross-selling opportunities already identified, positioning the company for its stated goal of returning to growth in 2026, contingent on a market recovery.

Key Decisions for Investors

• Investors should exercise caution regarding near-term profitability, as the company's guidance for a full-year EBITDA loss implies a significant negative performance in H2 2025, contrasting sharply with the fee-supported profit of H1.
• Monitor the conversion rate of the £40 million weighted order book and look for signs of market normalization in human challenge trials, as the company's guidance for a return to growth in 2026 is heavily dependent on these factors.
• The strong cash position of over £23 million provides a significant buffer to navigate the current industry downturn and fund operations through the anticipated period of negative EBITDA.
• Evaluate the continued success of the CRS and Cryo Store integrations, as their contribution through cross-selling and cost synergies will be critical to offsetting weakness in the core challenge trial segment and supporting the long-term growth narrative.